XML 8 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Feb. 28, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Trading Symbol ALVR    
Entity Registrant Name ALLOVIR, INC.    
Entity Central Index Key 0001754068    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Current Fiscal Year End Date --12-31    
Document Annual Report true    
Document Transition Report false    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Entity Shell Company true    
Entity Public Float     $ 58.8
Entity Common Stock, Shares Outstanding   5,043,357  
Security12b Title Common Stock, par value $0.0001 per share    
Security Exchange Name NASDAQ    
Entity File Number 001-39409    
Entity Incorporation State Country Code DE    
Entity Tax Identification Number 83-1971007    
Entity Address Address Line1 PO Box 44, 1661 Massachusetts Avenue    
Entity Address City Or Town Lexington    
Entity Address State Or Province MA    
Entity Address Postal Zip Code 02420    
City Area Code 617    
Local Phone Number 433-2605    
Document Financial Statement Error Correction Flag false    
Auditor Firm ID 34    
Auditor Name Deloitte & Touche LLP    
Auditor Location Boston, Massachusetts    
Auditor Opinion

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of AlloVir, Inc. and subsidiaries (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows, for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.